Recce Pharmaceuticals Ltd
Research Recce Pharmaceuticals Ltd (RCE) on Bullrun: market cap AUD 99.38M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRCE
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 99.38M
- Financial periodFY2025
- Net income-AUD 21.43M
- Free cash flow-AUD 20.47M
Valuation Snapshot
latest market cap is AUD 99.38M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | -AUD 21.43M | -AUD 20.47M | n/a | -0.09 | AUD 10.45M | AUD 10.77M | -AUD 3.05M |
| FY2024 | n/a | -AUD 17.66M | -AUD 13.15M | n/a | -0.1 | AUD 4.62M | AUD 811.19K | -AUD 9.52M |
| FY2023 | n/a | -AUD 13.08M | -AUD 12.73M | n/a | -0.07 | AUD 1.56M | AUD 250.57K | -AUD 2.59M |
| FY2022 | n/a | -AUD 10.99M | -AUD 9.05M | n/a | -0.06 | AUD 11.58M | AUD 74.76K | AUD 10.06M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-03 | AUD 99.38M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic antiinfectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Recce Pharmaceuticals Ltd's market cap?
Recce Pharmaceuticals Ltd's market capitalization is AUD 99.38M.
What does Recce Pharmaceuticals Ltd do?
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic antiinfectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections.